TRVI
Trevi Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release form of nalbuphine that acts on opioid receptors in the cough reflex arc to treat chronic cough. Its lead program targets chronic cough tied to idiopathic pulmonary fibrosis, with additional programs for other interstitial lung diseases and refractory chronic cough. The company has kept worldwide commercial rights to Haduvio.
CUSIP: 89532M101HealthcareUS1 holder
Total Value
$14.70M
Total Shares
4.40M
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
